H.C. Wainwright Reiterates Buy Rating on Lipocine Inc (LPCN)

H.C. Wainwright analyst Yi Chen reiterated a Buy rating and $8.00 price target on Lipocine Inc (NASDAQ: LPCN).

The analyst commented: "Lipocine recently reported its 2Q25 financial results. Total revenue was $623K, including $123K royalty from TLANDO sales and $500K license revenue. Net loss was $2.2M, or ($0.41) per share, in line with our estimated loss of $2.2M. Importantly, the Phase 3 trial of LPCN 1154 in postpartum depression (PPD) is currently treating patients. According to the protocol, this randomized, blinded study is slated to enroll 80 women aged 15 years and older and diagnosed with severe PPD. In the experimental arm, patients would take oral LPCN 1154 tablets at home for 48 hours. In the comparator arm, patients would take placebo tablets for 48 hours. The primary efficacy endpoint is the change from baseline to Hour 60 in the Hamilton Depression Rating Scale (HAM-D), a widely recognized clinical measure of depression severity. Management expects to have the first DSMB meeting in 2H25, report topline results in 2Q26, and submit a 505(b)(2) new drug application (NDA) in the U.S. in mid-2026. We reiterate our Buy rating and $8 PT.

For an analyst ratings summary and ratings history on Lipocine Inc click here. For more ratings news on Lipocine Inc click here.

Shares of Lipocine Inc closed at $3.04 yesterday.

You May Also Be Interested In

• H.C. Wainwright Upgrades Prime Medicine (PRME) to Buy
• Needham Starts Solaris Energy Infrastructure (SEI) at Buy
• Taiwan Semi (TSM) PT Raised to $625 at Barclays